<?xml version="1.0" encoding="UTF-8"?>
<search_results count="7">
  <query>zepatier</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT02743897</nct_id>
    <title>Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Zepatier</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>40 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>823833</other_id>
    </other_ids>
    <first_received>April 15, 2016</first_received>
    <start_date>May 2016</start_date>
    <completion_date>August 2018</completion_date>
    <last_updated>May 26, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCV</acronym>
    <primary_completion_date>June 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Post-treatment sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Major adverse events attributable to HCV therapy in post-kidney transplant patients post-kidney transplant patients.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02743897</url>
  </study>
  <study rank="2">
    <nct_id>NCT02781649</nct_id>
    <title>Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>End-Stage Renal Disease</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Zepatier</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB00089751</other_id>
    </other_ids>
    <first_received>May 10, 2016</first_received>
    <start_date>June 2016</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>May 23, 2016</last_updated>
    <last_verified>May 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EXPANDER-1</acronym>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4</outcome_measure>
      <outcome_measure>Viral response</outcome_measure>
      <outcome_measure>Antibody development</outcome_measure>
      <outcome_measure>Proportion of participants with Nonstructural protein 5A (NS5A) resistance mutations in the HCV population from the deceased donors</outcome_measure>
      <outcome_measure>IP-10 elevations</outcome_measure>
      <outcome_measure>Kidney function</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02781649</url>
  </study>
  <study rank="3">
    <nct_id>NCT02886624</nct_id>
    <title>Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 in HIV-infected Patients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir/Elbasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>Institut National de la Santé Et de la Recherche Médicale, France</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IMEA 50</other_id>
    </other_ids>
    <first_received>August 29, 2016</first_received>
    <start_date>September 2016</start_date>
    <completion_date>September 2018</completion_date>
    <last_updated>August 29, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SAHIV</acronym>
    <primary_completion_date>September 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 12 weeks post-treatment (SVR12)</outcome_measure>
      <outcome_measure>Virological failure</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>HIV RNA replication</outcome_measure>
      <outcome_measure>CD4 cell count</outcome_measure>
      <outcome_measure>Incidence of HCV re-infection</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02886624</url>
  </study>
  <study rank="4">
    <nct_id>NCT02785666</nct_id>
    <title>Swiss HCVree Trial</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">grazoprevir/elbasvir, ribavirin</intervention>
      <intervention type="Behavioral">Behavioural Intervention</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BASEC 2016-00131</other_id>
    </other_ids>
    <first_received>May 17, 2016</first_received>
    <start_date>June 2016</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>July 11, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCVree</acronym>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological efficacy of grazoprevir/elbasvir ±ribavirin: SVR rates at week 12 after treatment stop.</outcome_measure>
      <outcome_measure>Safety of grazoprevir/elbasvir ±ribavirin: frequency of adverse events and serious adverse events.</outcome_measure>
      <outcome_measure>Change in condom use before and after the behavioural Intervention</outcome_measure>
      <outcome_measure>Change in recreational drug use before and after the behavioural intervention</outcome_measure>
      <outcome_measure>Change in condom use attitude before and after the behavioural intervention</outcome_measure>
      <outcome_measure>Change in condom use self-efficacy before and after the behavioural intervention</outcome_measure>
      <outcome_measure>Change in condom use behaviour before and after the behavioural intervention</outcome_measure>
      <outcome_measure>Change in recreational drug use attitude before and after the behavioural intervention</outcome_measure>
      <outcome_measure>Change in recreational drug use behaviour before and after the behavioural intervention</outcome_measure>
      <outcome_measure>Change in recreational drug use self-efficacy before and after the behavioural intervention</outcome_measure>
      <outcome_measure>HCV treatment uptake: proportion of potentially eligible MSM participating in this study.</outcome_measure>
      <outcome_measure>Identification of presumed places of HCV acquisition and modes of HCV transmission: evaluation of patient's questionnaires</outcome_measure>
      <outcome_measure>Barriers to treatment: systematic documentation of exclusion reasons for HCV treatment by patient's questionnaire</outcome_measure>
      <outcome_measure>Adherence to HCV treatment: proportion of patients which are adherent to ≥95% of prescribed pills</outcome_measure>
      <outcome_measure>Impact of resistance associated variants: SVR 12 in GT 1a infected individuals stratified by presence of baseline RAV's.</outcome_measure>
      <outcome_measure>Assessment of HCV-specific cellular immune response: changes of HCV-specific T-cell functionality by ex vivo fluorescence-activated cell sorting (FACS) before and after DAA therapy</outcome_measure>
      <outcome_measure>Assessment of HCV-specific cellular immune response: changes of HCV-specific T-cell phenotype by ex vivo fluorescence-activated cell sorting (FACS) before and after DAA therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02785666</url>
  </study>
  <study rank="5">
    <nct_id>NCT02786537</nct_id>
    <title>Study of Oral Treatments for Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sofosbuvir/ledipasvir</intervention>
      <intervention type="Drug">ombitasvir/paritaprevir/ritonavir</intervention>
      <intervention type="Drug">elbasvir/grazoprevir</intervention>
      <intervention type="Drug">Dasabuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>Patient-Centered Outcomes Research Institute</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>3750</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>16-1234</other_id>
    </other_ids>
    <first_received>May 17, 2016</first_received>
    <start_date>June 2016</start_date>
    <completion_date>February 2021</completion_date>
    <last_updated>August 31, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PRIORITIZE</acronym>
    <primary_completion_date>August 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Patients who Achieve Undetectable Hepatitis C Virus (HCV) RNA 12 Weeks after completing HCV treatment</outcome_measure>
      <outcome_measure>Number of patients who report missing pills (doses) (Voils' Medication Adherence Survey)</outcome_measure>
      <outcome_measure>Number of patients with reduction in fibrosis 3 years (Liver Biopsy/Fibroscan) post treatment baseline</outcome_measure>
      <outcome_measure>Percentage of patients who are HCV RNA undetectable (cured) 3 years post-treatment</outcome_measure>
      <outcome_measure>Number of patients with decrease in HCV-associated symptoms (PROMIS measures) after HCV treatment initiation</outcome_measure>
      <outcome_measure>Percentage of patients who have an increase in functional status (as reported on HCV-PRO questionnaire)</outcome_measure>
      <outcome_measure>Number of participants with adverse events that caused treatment discontinuation</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arkansas</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02786537</url>
  </study>
  <study rank="6">
    <nct_id>NCT02647632</nct_id>
    <title>Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Grazoprevir/Elbasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC34 REVENGE</other_id>
    </other_ids>
    <first_received>December 16, 2015</first_received>
    <start_date>January 2016</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>July 19, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>rate of the Sustained Virological Response 12 weeks after the end of the therapy (SVR12), i.e. at W28 or W36 for treatment duration of 16 weeks and 24 weeks respectively.</outcome_measure>
      <outcome_measure>SVR rate 4 weeks after the end of treatment (i.e. at week 20 or week 28 for treatment duration of 16 weeks and 24 weeks respectively) and 24 weeks after the end of treatment (i.e. at week 40 or week 48).</outcome_measure>
      <outcome_measure>HCV viral load assessment</outcome_measure>
      <outcome_measure>Assessment of HCV subtypic distribution at baseline</outcome_measure>
      <outcome_measure>Numbers and proportions of patients presenting variants of resistance (RAV) at baseline</outcome_measure>
      <outcome_measure>Assessment of liver fibrosis by Hepatic impulse elastometry (Fibroscan®)</outcome_measure>
      <outcome_measure>For cirrhotic patients, description of the risk of cirrhosis evolution (decompensation, hepatocarcinoma)</outcome_measure>
      <outcome_measure>Clinical and biological adverse events occurring during the treatment and until 24 weeks after the end of the treatment</outcome_measure>
      <outcome_measure>Numbers and proportions of patients who interrupted the treatments of the study</outcome_measure>
      <outcome_measure>Patient's reported outcomes evaluation with questionnaires</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02647632</url>
  </study>
  <study rank="7">
    <nct_id>NCT02601820</nct_id>
    <title>The Patient-Reported Outcomes Project of HCV-TARGET</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Diseases</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>Patient-Centered Outcomes Research Institute</collaborator>
    </sponsors>
    <gender>Both</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>15-1633</other_id>
    </other_ids>
    <first_received>November 3, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>July 2018</completion_date>
    <last_updated>June 27, 2016</last_updated>
    <last_verified>June 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PROP-UP</acronym>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall Toxicity measured using the Memorial Symptom Assessment Scale</outcome_measure>
      <outcome_measure>Change in Treatment Related Symptoms</outcome_measure>
      <outcome_measure>Change in HCV-specific functional status</outcome_measure>
      <outcome_measure>Cumulative out of pocket costs during HCV treatment</outcome_measure>
      <outcome_measure>HCV medication adherence</outcome_measure>
      <outcome_measure>Change in HCV symptoms, side effects and functional status 3-months post treatment</outcome_measure>
      <outcome_measure>Changes in HCV symptoms, side effects and functional status 1 year post treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02601820</url>
  </study>
</search_results>
